Study of BLU-808 in Healthy Adult Participants
Completed · Phase 1 · Has a placebo group
Conditions studied: Healthy Participants
In brief
This is a 3-part study. Parts 1 and 2 are randomized, double-blind, placebo-controlled investigations of single ascending doses (SAD) (Part 1) and multiple ascending doses (MAD) (Part 2) of orally administered BLU-808 in healthy adult participants. Part 2 will also include an evaluation of the effect of multiple doses of BLU-808 on the single-dose pharmacokinetics (PK) of midazolam. Part 3 is an open-label, 2-sequence, 2-period, food effect (FE) study in healthy adult participants.
Key facts
- Study ID
- NCT06948032
- Run by
- Blueprint Medicines Corporation
- People needed
- 95
- Starts
- 2024-08-07
- Expected to finish
- 2025-01-21
- Last updated by the study team
- 2025-04-28
Who can join
Age: 19 and older, up to 65. Sex: any. Healthy volunteers: accepted.
Where it is running
- Celerion, Inc. — Lincoln, Nebraska, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.